Icosapent Ethyl Decreases Cardiovascular Event Risk in Metabolic Syndrome Without T2D

Icosapent ethyl in patients with metabolic syndrome without diabetes receiving statin therapy can reduce risk for cardiovascular events.

Related Keywords

,European Heart Journal ,Cardiovascular Events ,Icosapent Ethyl Trial ,